Wei Wei
Impact in
- Biomaterials top 0.1%
- Nanoparticle-Based Drug Delivery
- Pharmaceutical Science top 0.1%
- Advanced Drug Delivery Systems
Papers in
- Biomaterials 75
- Nanoparticle-Based Drug Delivery 65
-
- Advanced Drug Delivery Systems 25
- Co-authors
- Guanghui Ma (113 shared papers)Hua Yue (48 shared papers)Zhiguo G. Su (28 shared papers)Shuang Wang (35 shared papers)Feng Li (32 shared papers)Piping Lv (13 shared papers)Zhanguo Yue (12 shared papers)Lian-Yan Wang (9 shared papers)
- Journals
- Nature Communications (13 papers)Small (12 papers)Advanced Materials (10 papers)Advanced Functional Materials (10 papers)ACS Nano (8 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Wei Wei
569 papers receiving 24.4k citations
Wei Wei's Hit Papers
Peers
Comparison fields: 5 of 173
- Biomaterials 3.8k
- Pharmaceutical Science 1.5k
- Biomedical Engineering 4.6k
- Immunology 2.1k
- Catalysis 535
Countries citing papers authored by Wei Wei
This map shows the geographic impact of Wei Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Wei more than expected).
Fields of papers citing papers by Wei Wei
This network shows the impact of papers produced by Wei Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Wei. The network helps show where Wei Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 590 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 556 | |
| 2 | 2011 | 520 | |
| 3 | 2008 | 461 | |
| 4 | 2008 | 428 | |
| 5 | 2012 | 390 | |
| 6 | Immunomodulation‐Enhanced Nanozyme‐Based Tumor Catalytic Therapy Hit paper breakdown → | 2020 | 358 |
| 7 | 2012 | 354 | |
| 8 | 2018 | 340 | |
| 9 | 2019 | 337 | |
| 10 | Engineering Magnetosomes for Ferroptosis/Immunomodulation Synergism in Cancer Hit paper breakdown → | 2019 | 334 |
| 11 | 2007 | 300 | |
| 12 | 2011 | 282 | |
| 13 | 2018 | 281 | |
| 14 | 2010 | 280 | |
| 15 | 2020 | 275 | |
| 16 | 2013 | 273 | |
| 17 | 2018 | 244 | |
| 18 | 2011 | 227 | |
| 19 | 2014 | 223 | |
| 20 | 2016 | 221 |
About Wei Wei
Wei Wei is a scholar working on Biomaterials, Pharmaceutical Science, Biomedical Engineering, Molecular Biology and Immunology, having authored 590 papers that have together received 24.9k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (65 papers), Nanoplatforms for cancer theranostics (43 papers), Immunotherapy and Immune Responses (29 papers), Advanced Drug Delivery Systems (25 papers), Rheumatoid Arthritis Research and Therapies (19 papers), CAR-T cell therapy research (18 papers), Extracellular vesicles in disease (17 papers) and Enzyme Catalysis and Immobilization (14 papers). The work is most often cited by research in Biomaterials (3.8k citations), Pharmaceutical Science (1.5k citations), Biomedical Engineering (4.6k citations), Immunology (2.1k citations) and Catalysis (535 citations). Wei Wei has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Guanghui Ma, Hua Yue, Zhiguo G. Su, Shuang Wang, Feng Li, Piping Lv, Zhanguo Yue, Lian-Yan Wang, Xiaoyong Gao and Weier Bao. Their work appears in journals such as Nature Communications, Small, Advanced Materials, Advanced Functional Materials and ACS Nano.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.